May 23rd 2017
Richard R. Furman, MD, discusses the continued evolution of the field of chronic lymphocytic leukemia and how physicians decide on the optimal treatment sequence for their patients.
May 22nd 2017
Arjun V. Balar, MD, discusses the impact of the approval of pembrolizumab and other immunotherapy agents in urothelial carcinoma, as well as the next steps with these treatments.
May 19th 2017
Louise Davies, MD, discusses the experience of patients with incidentally identified thyroid cancer who choose to not receive treatment.
May 16th 2017
Mary C. White, ScD, MPH, discusses the unmet needs near and after the stopping age for cervical cancer screening.
May 12th 2017
Bradley C. Leibovich, MD, discusses the benefits of surgery and the need for more effective drug treatments for patients with metastatic renal cell carcinoma.
Raquibul Hannan, MD, PhD, discusses the benefits of using stereotactic radiation for patients with renal cell carcinoma and highlights ongoing trials examining the modality.
May 10th 2017
Gail J. Roboz, MD, discusses the recent FDA approval of midostaurin and what else is emerging in the treatment landscape in AML.
May 8th 2017
Sattva S. Neelapu, MD, discusses the ZUMA-1 trial and the potential impact of these results on patients with non-Hodgkin lymphoma.
Christopher J. Kane, MD, discusses the challenges and impact of genetic testing on patients with prostate cancer.
Steven Coutre, MD, discusses ongoing efforts to enhance frontline outcomes for patients with CLL.
May 3rd 2017
Debu Tripathy, MD, discusses current and emerging treatment strategies in the neoadjuvant setting for patients with HER2-postive breast cancer.
Benjamin L. Judson, MD, highlights the importance of a multidisciplinary team and shares insight on some of the advancements related to surgery for patients with head and neck cancer.
April 25th 2017
Barbara Burtness, MD, discusses her presentation on the current and emerging role of immunotherapy for patients with head and neck cancer.
April 24th 2017
Shana Wingo, MD, discusses the advancements being made in the field of surgery for patients with gynecologic cancers.
Suzanne George, MD, discusses an exceptional responder to pembrolizumab in leiomyosarcoma and the significance of these findings for further immunotherapy advances in the field.
April 15th 2017
Robert Dreicer, MD, highlights several emerging treatments for patients with metastatic castration-resistant prostate cancer.
April 13th 2017
Nathan Fowler, MD, discusses the current management of high-risk follicular lymphoma and ongoing developments in the field.
Shlomo Koyfman, MD, discusses the findings of a recent study of patients with HPV-positive oropharyngeal cancer treated with cisplatin-based chemoradiotherapy or cetuximab-based bioradiotherapy.
John L. Marshall, MD, discusses the results of the CALGB 80405 trial and other ongoing efforts to determine the underlying molecular basis for the sidedness issue in colorectal cancer.
April 11th 2017
Manish Shah, MD, discusses ongoing efforts to understand the distinction between early-onset CRC and traditional CRC.